Diana Perkinson Buys Shares of Omeros Corporation
Diana Perkinson acquired 15,000 shares of Omeros Corporation on June 18, 2026.
Key Points
- Diana Perkinson acquired 15,000 shares of Omeros Corporation on June 18, 2026, as part of recent insider activity.
- Omeros Corporation, trading under OMER on NasdaqGM, has a market cap of about $744 million with a P/E ratio of 9.02.
- Analyst firms like HC Wainwright & Co. and D. Boral Capital maintain a 'buy' rating for Omeros, with price targets up to $45.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Diana Perkinson bought 15,000 shares of Omeros Corporation on June 18, 2026. This purchase is part of recent insider activity at the biotech firm, which trades on the NasdaqGM under the ticker OMER.
Insider Buying and Selling at Omeros Corporation
In addition to Diana Perkinson, several other insiders, including Leroy Hood, Rajiv Shah, and Thomas Bumol, each bought 15,000 shares of Omeros Corporation on June 18, 2026. These transactions were not part of any pre-planned trading program.
Omeros Corporation Stock Down 44.5%
Shares of NasdaqGM:OMER traded near $10.28 on Monday. Omeros Corporation, a biotech company based in Seattle, has a market cap of approximately $744 million. The stock has a P/E ratio of 9.02 and a beta of 2.53. Over the past year, its stock price ranged from a low of $2.95 to a high of $17.65. The company's 50-day moving average is $12.22, and its 200-day moving average is $10.11.
$OMER stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analyst firms remain optimistic about Omeros Corporation's prospects. On April 21, 2026, D. Boral Capital maintained a 'buy' rating with a $36 price target. Similarly, HC Wainwright & Co. maintained their 'buy' rating with a target price of $40 back in January 2026. The consensus among analysts is a 'buy' with an average target price of $40, supported by one analyst opinion.
About Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company based in Seattle, Washington. It focuses on discovering, developing, and commercializing small-molecule and protein therapeutics for immunologic diseases. The company's lead product candidate is Narsoplimab, which is being developed for various serious conditions, including COVID-19 and acute respiratory distress syndrome. Omeros was founded in 1994 and is led by CEO Dr. Gregory A. Demopulos.
Bottom Line
Diana Perkinson's recent purchase of Omeros shares is part of a broader insider buying pattern at the company. Omeros, with its focus on innovative biotech solutions, continues to capture investor interest. Analysts maintain a positive outlook, as reflected in their 'buy' ratings and high price targets. Investors should note that insider transactions like these can provide insights into company sentiment, though they are not necessarily indicative of future stock performance.
Get Omeros Corporation alerts
New 13F filings, insider trades, and analyst moves on $OMER, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.